| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 1956* | 2021 |
| 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial A Halliday, M Harrison, E Hayter, X Kong, A Mansfield, J Marro, H Pan, ... The Lancet 376 (9746), 1074-1084, 2010 | 1122 | 2010 |
| A quantitative protein interaction network for the ErbB receptors using protein microarrays RB Jones, A Gordus, JA Krall, G MacBeath Nature 439 (7073), 168-174, 2005 | 933 | 2005 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 517* | 2021 |
| Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4 C Yu, F Wang, M Kan, C Jin, RB Jones, M Weinstein, CX Deng, ... Journal of Biological Chemistry 275 (20), 15482-15489, 2000 | 433 | 2000 |
| Innate immune and chemically triggered oxidative stress modifies translational fidelity N Netzer, JM Goodenbour, A David, KA Dittmar, RB Jones, JR Schneider, ... Nature 462 (7272), 522-526, 2009 | 384 | 2009 |
| System and method for detecting fraudulent transactions J Hillmer, R Jones, C Gessner, C Johnston, K Lewis, S Deshpande US Patent App. 10/298,814, 2003 | 378 | 2003 |
| Start-up, operation, monitoring and control of high-rate anaerobic treatment systems RF Hickey, WM Wu, MC Veiga, R Jones Water Science and Technology 24 (8), 207-255, 1991 | 337 | 1991 |
| System and method for detecting fraudulent transactions JM Hillmer, RA Jones, CM Gessner, CS Johnston, KR Lewis Jr, ... US Patent 6,714,918, 2004 | 331 | 2004 |
| Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study WJ Sandborn, S Travis, L Moro, R Jones, T Gautille, R Bagin, M Huang, ... Gastroenterology 143 (5), 1218-1226. e2, 2012 | 322 | 2012 |
| Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study SPL Travis, S Danese, L Kupcinskas, O Alexeeva, G D'Haens, PR Gibson, ... Gut 63 (3), 433-441, 2014 | 309 | 2014 |
| Fournier’s syndrome: necrotizing subcutaneous infection of the male genitalia RB Jones, JV Hirschmann, GS Brown, JA Tremann The Journal of urology 122 (3), 279-282, 1979 | 291 | 1979 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 273 | 2022 |
| A theoretical approach to the deformation of honeycomb based composite materials FK Abd El-Sayed, R Jones, IW Burgess Composites 10 (4), 209-214, 1979 | 243 | 1979 |
| Systems analysis of EGF receptor signaling dynamics with microwestern arrays MF Ciaccio, JP Wagner, CP Chuu, DA Lauffenburger, RB Jones Nature methods 7 (2), 148-155, 2010 | 240 | 2010 |
| First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial SM Lee, I Khan, S Upadhyay, C Lewanski, S Falk, G Skailes, E Marshall, ... The lancet oncology 13 (11), 1161-1170, 2012 | 218 | 2012 |
| Systematic discovery of TLR signaling components delineates viral-sensing circuits N Chevrier, P Mertins, MN Artyomov, AK Shalek, M Iannacone, ... Cell 147 (4), 853-867, 2011 | 217 | 2011 |
| A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain J Wojcik, O Hantschel, F Grebien, I Kaupe, KL Bennett, J Barkinge, ... Nature structural & molecular biology 17 (4), 519-527, 2010 | 206 | 2010 |
| Structural basis for interaction of FGF-1, FGF-2, and FGF-7 with different heparan sulfate motifs S Ye, Y Luo, W Lu, RB Jones, RJ Linhardt, I Capila, T Toida, M Kan, ... Biochemistry 40 (48), 14429-14439, 2001 | 191 | 2001 |
| An important role for CDK2 in G1 to S checkpoint activation and DNA damage response in human embryonic stem cells I Neganova, F Vilella, SP Atkinson, M Lloret, JF Passos, T Von Zglinicki, ... Stem Cells 29 (4), 651-659, 2011 | 176 | 2011 |
Mark F. CiaccioAbbVie, Microwestern Life Sciences, Northwestern University, University of ChicagoVerified email at abbvie.com
